Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ragweed sublingual tablet versus placebo for ragweed-induced rhinoconjunctivitis in adults
2008-003864-20Phase 2Completed
- Sponsor
- Schering AG
- Start
- Nov 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and ragweed allergy comparing SCH 39641 sublingual tablet with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Nov 2008; status: completed.
02
Drugs
ambrosia artemisiifolia allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)ragweed allergy
Beyond the preview
Go deeper on 2008-003864-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003864-20.